Peroxisome proliferator-activated receptor gamma and its natural agonists in the treatment of kidney diseases

被引:28
作者
Sharma, Vinesh [1 ,2 ]
Patial, Vikram [1 ,2 ]
机构
[1] Inst Himalayan Bioresource Technol, Dietet & Nutr Technol Div, Pharmacol & Toxicol Lab, CSIR, Palampur, HP, India
[2] Acad Sci & Innovat Res AcSIR, Ghaziabad, UP, India
关键词
kidney diseases; natural agonists; PPAR-gamma; synthetic agonists; pathophysiology; ZHEN-WU-TANG; PPAR-GAMMA; DIABETIC-NEPHROPATHY; OXIDATIVE STRESS; IGA NEPHROPATHY; METABOLIC SYNDROME; INJURY; SUPPLEMENTATION; HYPERTENSION; INFLAMMATION;
D O I
10.3389/fphar.2022.991059
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Kidney disease is one of the leading non-communicable diseases related to tremendous health and economic burden globally. Diabetes, hypertension, obesity and cardiovascular conditions are the major risk factors for kidney disease, followed by infections, toxicity and autoimmune causes. The peroxisome proliferator-activated receptor gamma (PPAR-gamma) is a ligand-activated nuclear receptor that plays an essential role in kidney physiology and disease. The synthetic agonists of PPAR-gamma shows a therapeutic effect in various kidney conditions; however, the associated side effect restricts their use. Therefore, there is an increasing interest in exploring natural products with PPAR gamma-activating potential, which can be a promising solution to developing effective and safe treatment of kidney diseases. In this review, we have discussed the role of PPAR-gamma in the pathophysiology of kidney disease and the potential of natural PPAR-gamma agonists in treating various kidney diseases, including acute kidney injury, diabetic kidney disease, obesity-induced nephropathy, hypertension nephropathy and IgA nephropathy. PPAR-gamma is a potential target for the natural PPAR-gamma agonists against kidney disease; however, more studies are required in this direction.
引用
收藏
页数:18
相关论文
共 94 条
[31]   Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet [J].
Kume, Shinji ;
Uzu, Takashi ;
Araki, Shin-ichi ;
Sugimoto, Toshiro ;
Isshiki, Keiji ;
Chin-Kanasaki, Masami ;
Sakaguchi, Masayoshi ;
Kubota, Naoto ;
Terauchi, Yasuo ;
Kadowaki, Takashi ;
Haneda, Masakazu ;
Kashiwagi, Atsunori ;
Koya, Daisuke .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (10) :2715-2723
[32]   Additive effect of PPAR-γ agonist and ARB in treatment of experimental IgA nephropathy [J].
Lai, Kar Neng ;
Chan, Loretta Y. Y. ;
Guo, Hong ;
Tang, Sydney C. W. ;
Leung, Joseph C. K. .
PEDIATRIC NEPHROLOGY, 2011, 26 (02) :257-266
[33]   Thiazolidinediones: the Forgotten Diabetes Medications [J].
Lebovitz, Harold E. .
CURRENT DIABETES REPORTS, 2019, 19 (12)
[34]   Monascin improves diabetes and dyslipidemia by regulating PPARγ and inhibiting lipogenesis in fructose-rich diet-induced C57BL/6 mice [J].
Lee, Bao-Hong ;
Hsu, Wei-Hsuan ;
Huang, Tao ;
Chang, Yu-Yin ;
Hsu, Ya-Wen ;
Pan, Tzu-Ming .
FOOD & FUNCTION, 2013, 4 (06) :950-959
[35]   Tocotrienol-rich fraction supplementation reduces hyperglycemia-induced skeletal muscle damage through regulation of insulin signaling and oxidative stress in type 2 diabetic mice [J].
Lee, Heaji ;
Lim, Yunsook .
JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2018, 57 :77-85
[36]   PPARγ and the global map of adipogenesis and beyond [J].
Lefterova, Martina I. ;
Haakonsson, Anders K. ;
Lazar, Mitchell A. ;
Mandrup, Susanne .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2014, 25 (06) :293-302
[37]   Distinct functions of PPARγ isoforms in regulating adipocyte plasticity [J].
Li, Dylan ;
Zhang, Feng ;
Zhang, Xuan ;
Xue, Chenyi ;
Namwanje, Maria ;
Fan, Lihong ;
Reilly, Muredach P. ;
Hu, Fang ;
Qiang, Li .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 481 (1-2) :132-138
[38]   EPA and DHA reduce LPS-induced inflammation responses in HK-2 cells:: Evidence for a PPAR-γ-dependent mechanism [J].
Li, H ;
Ruan, XZ ;
Powis, SH ;
Fernando, R ;
Mon, WY ;
Wheeler, DC ;
Moorhead, JF ;
Varghese, Z .
KIDNEY INTERNATIONAL, 2005, 67 (03) :867-874
[39]   Diabetic nephropathy - complications and treatment [J].
Lim, Andy K. H. .
INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE, 2014, 7 :361-381
[40]   Supplementation with high-dose trans-resveratrol improves ultrafiltration in peritoneal dialysis patients: a prospective, randomized, double-blind study [J].
Lin, Chong-Ting ;
Sun, Xiao-Yan ;
Lin, Ai-Xia .
RENAL FAILURE, 2016, 38 (02) :214-221